Hospital

The agent continues to show promising clinical benefit despite being pulled from the market in 2023.

A groundbreaking trial shows zimislecel significantly reduces insulin dependence in type 1 diabetes patients, offering hope for a functional cure.

The Advisory Committee on Immunization Practices (ACIP) voted 5-1, with 1 voter abstaining, to recommend that adults receive seasonal influenza vaccines that do not contain the preservative thimerosal.

A pharmacist-led program effectively reduces incorrect penicillin allergy labels, promoting better antibiotic use and enhancing patient care in intensive care units.

Health care professionals are encouraged to educate patients on potential cannabis-related risks to cardiovascular health.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.

The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.

Hospitals and health systems proactively monitor and manage data accuracy with third-party administrators to maintain 340B program compliance and maximize benefits for vulnerable patient populations.

Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.

Oral semaglutide shows promising cardiovascular benefits for type 2 diabetes patients, reducing major adverse events by 14% in the SOUL trial.

CagriSema shows promising weight loss and metabolic benefits in recent trials, offering new hope for obesity and type 2 diabetes management.

Experts discuss the low prescription rates of ready-to-use glucagon for individuals with diabetes.

Semaglutide shows promise in enhancing walking ability and reducing disease progression in patients with type 2 diabetes and peripheral artery disease.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.

Jolynn Sessions, PharmD, BCOP, FHOPA, shares her experience as a clinical pharmacist and the value of the Oncology Pharmacists Connect meeting.

Victoria Nacher, PharmD, BCOP, offers key insights about the evolving treatment landscape for hematologic malignancies.

Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from frontline immune checkpoint inhibitor (ICI) therapy.

In today’s rapidly evolving health care landscape, pharmacists are playing an increasingly vital role in patient care—but many policymakers remain unaware of the full scope of their expertise and contributions.

The emergence of biomarkers plays a critical role in the growing success of treatment.

Tim Mok, PharmD, BCOP, BCPS, discusses emerging advancements in treatment of leukemia and lymphoma.

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

When infected with SARS-CoV-2, the virus that causes COVID-19, higher levels of proinflammatory cytokines are released in men compared with women, leading to more severe disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.